National Cancer Institute; Notice of Closed Meetings, 49383-49384 [E9-23269]
Download as PDF
<![CDATA[
49383
Federal Register / Vol. 74, No. 186 / Monday, September 28, 2009 / Notices
systems development and on services
that children and families receive. The
electronic data reports also will collect
data about other Project LAUNCHfunded service enhancements, such as
trainings, Project LAUNCH systems
change activities, and changes in
provider settings. Information provided
in these reports will be aggregated on a
quarterly basis, and reported semiannually.
Respondents: State/Tribal Child
Wellness Coordinator, State/Tribal
Wellness Council Members, State ECCS
Project Director, Local Child Wellness
Coordinator, Local Wellness Council
Members, Local Evaluator, and Local
Service Providers.
ANNUAL BURDEN ESTIMATES’>
Annual
number of
respondents
Instrument
Site Visit Interview Guide ................................................................................
Electronic Data Reporting: Systems Measures ...............................................
Electronic Data Reporting: Services Measures ...............................................
Estimated Annual Burden Hours: 702
hours.
Additional Information
Copies of the proposed collection may
be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade, SW., Washington, DC
20447, Attn: OPRE Reports Clearance
Officer. All requests should be
identified by the title of the information
collection. E-mail address:
OPREinfocol1ection@acf.hhs.gov.
OMB Comment
OMB is required to make a decision
concerning the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication. Written comments and
recommendations for the proposed
information collection should be sent
directly to the following: Office of
Management and Budget, Paperwork
Reduction Project, Fax: 202–395–6974.
Attn: Desk Officer for the
Administration for Children and
Families.
Dated: September 17, 2009.
Seth F. Chamberlain,
OPRE Reports Clearance Officer.
[FR Doc. E9–23242 Filed 9–25–09; 8:45 am]
srobinson on DSKHWCL6B1PROD with NOTICES
BILLING CODE M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Nov<24>2008
16:33 Sep 25, 2009
Jkt 217001
216
18
18
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National
Institute of Mental Health Special
Emphasis Panel. K99.
Date: October 29, 2009.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
(Telephone Conference Call).
Contact Person: Megan Libbey, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute
of Mental Health, NIH, Neuroscience
Center, 6001 Executive Blvd., Room
6148, MSC 9609, Rockville, MD 20852–
9609. 301–402–6807.
libbeym@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: September 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23337 Filed 9–25–09; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
2
2
Average
burden hours
per response
Estimated
annual burden
hours
1.25
4
8
270
144
288
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel.
Pharmacodynamic Assays for Cancer
Therapeutics.
Date: October 6, 2009.
Time: 11 a.m. to 1:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6116
Executive Boulevard, Room # 210, Rockville,
MD 20852. (Telephone Conference Call).
Contact Person: Thomas M Vollberg, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 7142, Bethesda,
MD 20892. 301–594–9582.
vollbert@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
conflicts.
Name of Committee: National Cancer
Institute Special Emphasis Panel. R13
Conference Grants Review.
Date: October 29, 2009.
Time: 1 p.m. to 5 p.m.
E:\FR\FM\28SEN1.SGM
28SEN1
49384
Federal Register / Vol. 74, No. 186 / Monday, September 28, 2009 / Notices
srobinson on DSKHWCL6B1PROD with NOTICES
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6116
Executive Boulevard, 8041, Rockville, MD
20852. (Telephone Conference Call).
Contact Person: Bratin K. Saha, PhD,
Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 8041, Bethesda, MD 20892. (301) 402–
0371. sahab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel. NCI Cancer
Prevention Research II.
Date: October 30, 2009.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6116
Executive Boulevard, Room # 210, Rockville,
MD 20852. (Telephone Conference Call).
Contact Person: Irina Gordienko, PhD,
Scientific Review Officer, Scientific Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Blvd., Rm. 7073, Bethesda,
MD 20892. 301–594–1566.
gordienkoiv@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel.
Community Clinical Oncology Programs.
Date: December 1–2, 2009.
Time: 7 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Courtyard Gaithersburg
Washingtonian Ctr, 204 Boardwalk Place,
Gaithersburg, MD 20878.
Contact Person: Gerald G. Lovinger, PhD,
Scientific Review Administrator, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8101,
Bethesda, MD 20892–8329. 301/496–7987.
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23269 Filed 9–25–09; 8:45 am]
BILLING CODE 4140–01–P
VerDate Nov<24>2008
16:33 Sep 25, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Pulmonary-Allergy Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pulmonary-Allergy
Drugs Advisory Committee.
General Function of the Committee: To
provide advice and recommendations to the
agency on FDA’s regulatory issues.
Date and Time: The meeting will be held
on November 18, 2009, from 8 a.m. to 5 p.m.
Location: Hilton Washington DC/Silver
Spring, The Ballrooms, 8727 Colesville Rd.,
Silver Spring, MD. The hotel phone number
is 301–589–5200.
Contact Person: Kristine T. Khuc, Center
for Drug Evaluation and Research (HFD–21),
Food and Drug Administration, 5600 Fishers
Lane (for express delivery, 5630 Fishers
Lane, rm. 1093), Rockville, MD 20857, 301–
827–7001, FAX: 301–827–6776, e-mail:
Kristine.Khuc@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–741–
8138 (301–443–0572 in the Washington, DC
area), code 3014512545. Please call the
Information Line for up-to-date information
on this meeting. A notice in the Federal
Register about last minute modifications that
impact a previously announced advisory
committee meeting cannot always be
published quickly enough to provide timely
notice. Therefore, you should always check
the agency’s Web site and call the
appropriate advisory committee hot line/
phone line to learn about possible
modifications before coming to the meeting.
Agenda: The committee will discuss
biologics license application (BLA) 103976,
supplement 5149, for XOLAIR (omalizumab),
manufactured by Genentech USA, Inc. and
Novartis Pharmaceuticals Corp. The
proposed indication for this product is to
treat moderate to severe persistent asthma in
patients between 6 and 11 years of age whose
symptoms are inadequately controlled with
inhaled steroid medications and have: (1) A
positive reaction to skin testing with
common substances that can cause allergies
and asthma, such as pollen or (2) in vitro
reactivity, which is measured with a blood
test that confirms the presence of specific
proteins consistent with allergies and
asthma.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
November 3, 2009. Oral presentations from
the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
desiring to make formal oral presentations
should notify the contact person and submit
a brief statement of the general nature of the
evidence or arguments they wish to present,
the names and addresses of proposed
participants, and an indication of the
approximate time requested to make their
presentation on or before October 26, 2009.
Time allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can be
reasonably accommodated during the
scheduled open public hearing session, FDA
may conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by October 27, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Kristine T.
Khuc at least 7 days in advance of the
meeting.
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for procedures
on public conduct during advisory
committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: September 22, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–23292 Filed 9–25–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Pulmonary-Allergy Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
E:\FR\FM\28SEN1.SGM
Notice.
28SEN1
]]>Agencies
[Federal Register Volume 74, Number 186 (Monday, September 28, 2009)]
[Notices]
[Pages 49383-49384]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23269]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel. Pharmacodynamic Assays for Cancer Therapeutics.
Date: October 6, 2009.
Time: 11 a.m. to 1:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6116 Executive Boulevard,
Room 210, Rockville, MD 20852. (Telephone Conference
Call).
Contact Person: Thomas M Vollberg, PhD, Scientific Review
Officer, Special Review and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116 Executive Boulevard,
Room 7142, Bethesda, MD 20892. 301-594-9582. vollbert@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to scheduling conflicts.
Name of Committee: National Cancer Institute Special Emphasis
Panel. R13 Conference Grants Review.
Date: October 29, 2009.
Time: 1 p.m. to 5 p.m.
[[Page 49384]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6116 Executive Boulevard,
8041, Rockville, MD 20852. (Telephone Conference Call).
Contact Person: Bratin K. Saha, PhD, Scientific Review Officer,
Program Coordination and Referral Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 6116 Executive
Boulevard, Room 8041, Bethesda, MD 20892. (301) 402-0371.
sahab@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel. NCI Cancer Prevention Research II.
Date: October 30, 2009.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6116 Executive Boulevard,
Room 210, Rockville, MD 20852. (Telephone Conference
Call).
Contact Person: Irina Gordienko, PhD, Scientific Review Officer,
Scientific Review and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 6116 Executive Blvd.,
Rm. 7073, Bethesda, MD 20892. 301-594-1566.
gordienkoiv@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel. Community Clinical Oncology Programs.
Date: December 1-2, 2009.
Time: 7 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: Marriott Courtyard Gaithersburg Washingtonian Ctr, 204
Boardwalk Place, Gaithersburg, MD 20878.
Contact Person: Gerald G. Lovinger, PhD, Scientific Review
Administrator, Special Review and Logistics Branch, Division of
Extramural Activities, National Cancer Institute, 6116 Executive
Blvd., Room 8101, Bethesda, MD 20892-8329. 301/496-7987.
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: September 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-23269 Filed 9-25-09; 8:45 am]
BILLING CODE 4140-01-P
